Barbara Bohle

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4840086/publications.pdf

Version: 2024-02-01

158	7,531	57758	62596
papers	citations	44 h-index	80 g-index

164	164	164	5673
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	EAACI Molecular Allergology User's Guide. Pediatric Allergy and Immunology, 2016, 27, 1-250.	2.6	642
2	Sublingual immunotherapy induces IL-10â€“producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. Journal of Allergy and Clinical Immunology, 2007, 120, 707-713.	2.9	388
3	Apple allergy across Europe: How allergen sensitization profiles determine the clinical expression of allergies to plant foods. Journal of Allergy and Clinical Immunology, 2006, 118, 481-488.	2.9	308
4	Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH₂ to TH₁ in Tâ€cell clones specific for Phi p 1, a major grass pollen allergen. Clinical and Experimental Allergy, 1997, 27, 1007-1015.	2.9	288
5	Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1156-1173.	5.7	275
6	Birch pollenâ€“related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies. Journal of Allergy and Clinical Immunology, 2011, 127, 616-622.e1.	2.9	198
7	Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-Î³ production in cells from allergic individuals and inhibit IgE synthesisin vitro. European Journal of Immunology, 1999, 29, 2344-2353.	2.9	169
8	Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1â€“related food allergens. Journal of Allergy and Clinical Immunology, 2005, 116, 213-219.	2.9	147
9	Cooking birch pollenâ€“related food: Divergent consequences for IgE- and T cellâ€“mediated reactivity in vitro and in vivo. Journal of Allergy and Clinical Immunology, 2006, 118, 242-249.	2.9	147
10	AllergenOnline: A peerâ€reviewed, curated allergen database to assess novel food proteins for potential crossâ€reactivity. Molecular Nutrition and Food Research, 2016, 60, 1183-1198.	3.3	147
11	Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. Journal of Allergy and Clinical Immunology, 2007, 119, 937-943.	2.9	139
12	Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrology Dialysis Transplantation, 2012, 27, 226-230.	0.7	129
13	Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cellsâ˜†â˜†â˜†â˜…â˜…â˜…. Journal of Allergy and Clinical Immunology, 1998, 102, 679-686.	2.9	119
14	Systemic Immunological Changes Induced by Administration of Grass Pollen Allergens via the Oral Mucosa during Sublingual Immunotherapy. International Archives of Allergy and Immunology, 1999, 120, 218-224.	2.1	114
15	The impact of pollenâ€related food allergens on pollen allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 3-10.	5.7	112
16	Assessment of Bet v 1-Specific CD4+ T Cell Responses in Allergic and Nonallergic Individuals Using MHC Class II Peptide Tetramers. Journal of Immunology, 2008, 180, 4514-4522.	0.8	110
17	Purification and characterization of recombinant Bet v I, the major birch pollen allergen. Immunological equivalence to natural Bet v I.. Journal of Biological Chemistry, 1993, 268, 19574-19580.	3.4	102
18	EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clinical and Translational Allergy, 2012, 2, 20.	3.2	97

#	Article	IF	Citations
19	Betâ€„vâ€„1, the major birch pollen allergen, initiates sensitization to Apiâ€„gâ€„1, the major allergen in celery: evidence at the Tâ€„cell level. European Journal of Immunology, 2003, 33, 3303-3310.	2.9	90
20	Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organization Journal, 2016, 9, 33.	3.5	87
21	Gastrointestinal digestion of Bet v 1â€“homologous food allergens destroys their mediator-releasing, but not T cellâ€“activating, capacity. Journal of Allergy and Clinical Immunology, 2005, 116, 1327-1333.	2.9	83
22	Purification and characterization of recombinant Bet v I, the major birch pollen allergen. Immunological equivalence to natural Bet v I. Journal of Biological Chemistry, 1993, 268, 19574-80.	3.4	78
23	The immunological relationship of epitopes on major tree pollen allergens. Molecular Immunology, 1991, 28, 897-906.	2.2	74
24	Protein unfolding strongly modulates the allergenicity and immunogenicity of Pru p 3, the major peach allergen. Journal of Allergy and Clinical Immunology, 2011, 128, 1022-1030.e7.	2.9	74
25	Profiling of human CD4+ T-cell subsets identifies the TH2-specific noncoding RNA GATA3-AS1. Journal of Allergy and Clinical Immunology, 2013, 132, 1005-1008.	2.9	73
26	The Impact of Nitration on the Structure and Immunogenicity of the Major Birch Pollen Allergen Bet v 1.0101. PLoS ONE, 2014, 9, e104520.	2.5	70
27	Mutational Analysis of Amino Acid Positions Crucial for IgE-Binding Epitopes of the Major Apple (Malus domestica) Allergen, Mal d 1. International Archives of Allergy and Immunology, 2006, 139, 53-62.	2.1	69
28	Naturally processed T cellâ€“activating peptides of the major birch pollen allergen. Journal of Allergy and Clinical Immunology, 2010, 125, 711-718.e2.	2.9	69
29	The T Cell Response to Art v 1, the Major Mugwort Pollen Allergen, Is Dominated by One Epitope. Journal of Immunology, 2002, 169, 6005-6011.	0.8	67
30	Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant Bet v 1, the major birch pollen allergen, in a murine model of type I allergy. Journal of Allergy and Clinical Immunology, 1999, 103, 1202-1210.	2.9	66
31	Assessing Protein Immunogenicity with a Dendritic Cell Line-Derived Endolysosomal Degradome. PLoS ONE, 2011, 6, e17278.	2.5	64
32	Peptide mimotopes displayed by phage inhibit antibody binding to Bet v 1, the major birch pollen allergen, and induce specific IgG response in mice. FASEB Journal, 1998, 12, 1635-1642.	0.5	63
33	Antigen presentation of the immunodominant T-cell epitope of the major mugwort pollen allergen, Art v 1, is associated with the expression of HLA-DRB1â^—01. Journal of Allergy and Clinical Immunology, 2005, 115, 399-404.	2.9	62
34	A Novel Approach to Specific Allergy Treatment: The Recombinant Fusion Protein of a Bacterial Cell Surface (S-Layer) Protein and the Major Birch Pollen Allergen Bet v 1 (rSbsC-Bet v 1) Combines Reduced Allergenicity with Immunomodulating Capacity. Journal of Immunology, 2004, 172, 6642-6648.	0.8	61
35	Nitration of the Pollen Allergen Bet v 1.0101 Enhances the Presentation of Bet v 1-Derived Peptides by HLA-DR on Human Dendritic Cells. PLoS ONE, 2012, 7, e31483.	2.5	60
36	Human Th2 but Not Th9 Cells Release IL-31 in a STAT6/NF-ÎºBâ€“Dependent Way. Journal of Immunology, 2014, 193, 645-654.	0.8	57

#	Article	IF	Citations
37	A food matrix reduces digestion and absorption of food allergens in vivo. Molecular Nutrition and Food Research, 2011, 55, 1484-1491.	3.3	56
38	Efficacy and safety of 4Âmonths of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollenâ€"related apple allergy. Journal of Allergy and Clinical Immunology, 2018, 141, 1002-1008.	2.9	56
39	Intranasal Treatment with a Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1 Prevents Allergic Sensitization and Airway Inflammation in Mice. International Archives of Allergy and Immunology, 2001, 126, 68-77.	2.1	55
40	A recombinant bacterial cell surface (S-layer)-major birch pollen allergen-fusion protein (rSbsC/Bet) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 functionality of the allergen. Protein Engineering, Design and Selection, 2002, 15, 243-249.	2.1	53
41	Reshaping the Bet v 1 fold modulates TH polarization. Journal of Allergy and Clinical Immunology, 2011, 127, 1571-1578.e9.	2.9	53
42	Human blood basophils do not act as antigenâ€presenting cells for the major birch pollen allergen <scp>B</scp>et v 1. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 593-600.	5.7	52
43	Characterization of the T cell response to the major hazelnut allergen, Cor a 1.04: evidence for a relevant T cell epitope not crossâ€reactive with homologous pollen allergens. Clinical and Experimental Allergy, 2005, 35, 1392-1399.	2.9	45
44	Humoral and Cellular Cross-Reactivity between Amb a 1, the Major Ragweed Pollen Allergen, and Its Mugwort Homolog Art v 6. Journal of Immunology, 2012, 188, 1559-1567.	0.8	45
45	Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1377-1386.	5.7	45
46	A Novel Approach to Specific Allergy Treatment: The Recombinant Allergen-S-Layer Fusion Protein rSbsC-Bet v 1 Matures Dendritic Cells That Prime Th0/Th1 and IL-10-Producing Regulatory T Cells. Journal of Immunology, 2007, 179, 7270-7275.	0.8	44
47	Targeting the cysteine-stabilized fold of Art v 1 for immunotherapy of Artemisia pollen allergy. Molecular Immunology, 2010, 47, 1292-1298.	2.2	44
48	Pru p 3, the nonspecific lipid transfer protein from peach, dominates the immune response to its homolog in hazelnut. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1005-1013.	5.7	44
49	A novel role for neutrophils in IgE-mediated allergy: Evidence for antigen presentation in late-phase reactions. Journal of Allergy and Clinical Immunology, 2019, 143, 1143-1152.e4.	2.9	44
50	3-Layer-based analysis of peptideâ€"MHC interaction: In silico prediction, peptide binding affinity and T cell activation in a relevant allergen-specific model. Molecular Immunology, 2009, 46, 1839-1844.	2.2	43
51	Allergy multivaccines created by DNA shuffling of tree pollen allergens. Journal of Allergy and Clinical Immunology, 2007, 120, 374-380.	2.9	42
52	Update of the S2k guideline on the management of IgE-mediated food allergies. Allergologie Select, 2021, 5, 195-243.	3.1	42
53	Characterization of T Cell Responses to Hev b 3, an Allergen Associated with Latex Allergy in Spina Bifida Patients. Journal of Immunology, 2000, 164, 4393-4398.	0.8	40
54	Immunologic characterization of isoforms of Car b 1 and Que a 1, the major hornbeam and oak pollen allergens. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 452-460.	5.7	40

#	Article	IF	Citations
55	Correlation of sensitizing capacity and T-cell recognition within the Bet v 1 family. Journal of Allergy and Clinical Immunology, 2015, 136, 151-158.	2.9	40
56	Surface LAMP-2 Is an Endocytic Receptor That Diverts Antigen Internalized by Human Dendritic Cells into Highly Immunogenic Exosomes. Journal of Immunology, 2017, 199, 531-546.	0.8	40
57	Bet v 1 â€“ a Trojan horse for small ligands boosting allergic sensitization?. Clinical and Experimental Allergy, 2014, 44, 1083-1093.	2.9	38
58	The quantity and quality of Î±-gal-specific antibodies differ in individuals with and without delayed red meat allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 266-273.	5.7	38
59	Characterization of the human T cell response to antigen 5 from Vespula vulgaris (Ves v 5). Clinical and Experimental Allergy, 2005, 35, 367-373.	2.9	37
60	Characterization of the allergic T-cell response to Pru p 3, the nonspecific lipid transfer protein in peach. Journal of Allergy and Clinical Immunology, 2009, 124, 100-107.	2.9	36
61	T-Cell Epitopes of Food Allergens. Clinical Reviews in Allergy and Immunology, 2006, 30, 97-108.	6.5	35
62	Expression of an endotoxin-free S-layer/allergen fusion protein in gram-positive Bacillus subtilis 1012 for the potential application as vaccines for immunotherapy of atopic allergy. Microbial Cell Factories, 2011, 10, 6.	4.0	35
63	Enhanced Pru p 3 IgE-binding activity by selective free fatty acid-interaction. Journal of Allergy and Clinical Immunology, 2017, 140, 1728-1731.e10.	2.9	35
64	IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergy. Journal of Allergy and Clinical Immunology, 2020, 146, 894-900.e2.	2.9	34
65	Context matters: TH2 polarization resulting from pollen composition and not from protein-intrinsic allergenicity. Journal of Allergy and Clinical Immunology, 2018, 142, 984-987.e6.	2.9	33
66	Long-lived Th2 clones specific for seasonal and perennial allergens can be detected in blood and skin by their TCR-hypervariable regions. Journal of Immunology, 1998, 160, 2022-7.	0.8	33
67	Structural and immunological characterization of the N-glycans from the major yellow jacket allergen Ves v 2: The N-glycan structures are needed for the human antibody recognition. Molecular Immunology, 2009, 46, 2014-2021.	2.2	32
68	Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy. Journal of Allergy and Clinical Immunology, 2013, 131, 94-102.	2.9	32
69	Molecular and functional analysis of the antigen receptor of Art v 1â€“specific helper T lymphocytes. Journal of Allergy and Clinical Immunology, 2008, 121, 64-71.	2.9	31
70	Anaphylaxis to Buckwheat in an Atopic Child: A Risk Factor for Severe Allergy to Nuts and Seeds?. International Archives of Allergy and Immunology, 2011, 156, 112-116.	2.1	31
71	Differences in the intrinsic immunogenicity and allergenicity of <scp>B</scp> et v 1 and related food allergens revealed by siteâ€directed mutagenesis. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 208-215.	5.7	31
72	T lymphocytes and food allergy. Molecular Nutrition and Food Research, 2004, 48, 424-433.	3.3	29

#	Article	IF	Citations
73	Bet v 1â€“specific T-cell receptor/forkhead box protein 3 transgenic T cells suppress Bet v 1â€“specific T-cell effector function in an activation-dependent manner. Journal of Allergy and Clinical Immunology, 2011, 127, 238-245.e3.	2.9	29
74	Lessons from low seroprevalence of SARSâ€CoVâ€2 antibodies in schoolchildren: A crossâ€sectional study. Pediatric Allergy and Immunology, 2021, 32, 762-770.	2.6	29
75	The alpha and beta subchain of Amb a 1, the major ragweed-pollen allergen show divergent reactivity at the IgE and T-cell level. Molecular Immunology, 2009, 46, 2090-2097.	2.2	28
76	Recommendations for the allergy management in the primary care. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 708-718.	5.7	28
77	Expression and Characterization of Functional Recombinant Bet v 1.0101 in the Chloroplast of <i>Chlamydomonas reinhardtii</i>. International Archives of Allergy and Immunology, 2017, 173, 44-50.	2.1	28
78	Modulation of allergen-specific T-lymphocyte function by virus-like particles decorated with HLA class II molecules. Journal of Allergy and Clinical Immunology, 2009, 124, 121-128.	2.9	27
79	Tackling Bet v 1 and associated food allergies with a single hybrid protein. Journal of Allergy and Clinical Immunology, 2017, 140, 525-533.e10.	2.9	27
80	Immunological differences between insect venomâ€allergic patients with and without immunotherapy and asymptomatically sensitized subjects. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1223-1231.	5.7	27
81	A hypoallergenic variant of the major birch pollen allergen shows distinct characteristics in antigen processing and <scp>T</scp>â€cell activation. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1375-1382.	5.7	26
82	Differential activation of dendritic cells by tollâ€like receptors causes diverse differentiation of naÃ¯ve<scp>CD</scp>4⁺<scp>T</scp>cells from allergic patients. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1602-1609.	5.7	26
83	Amb a 1 isoforms: Unequal siblings with distinct immunological features. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1874-1882.	5.7	26
84	Association of HLA-DR1 with the allergic response to the major mugwort pollen allergen: molecular background. BMC Immunology, 2012, 13, 43.	2.2	25
85	Fusion proteins of flagellin and the major birch pollen allergen Bet v 1 show enhanced immunogenicity, reduced allergenicity, and intrinsic adjuvanticity. Journal of Allergy and Clinical Immunology, 2018, 141, 293-299.e6.	2.9	25
86	Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. Clinical and Translational Allergy, 2016, 6, 41.	3.2	24
87	Monitoring the epitope recognition profiles of IgE, IgG 1 , and IgG 4 during birch pollen immunotherapy. Journal of Allergy and Clinical Immunology, 2016, 137, 1600-1603.e1.	2.9	24
88	Genetic restriction of antigen-presentation dictates allergic sensitization and disease in humanized mice. EBioMedicine, 2018, 31, 66-78.	6.1	24
89	Allergy to millet: another risk for atopic bird keepers. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 325-328.	5.7	23
90	Critical role of mammalian target of rapamycin for IL-10 dendritic cell induction by a flagellin AÂconjugate in preventing allergic sensitization. Journal of Allergy and Clinical Immunology, 2018, 141, 1786-1798.e11.	2.9	23

#	Article	IF	Citations
91	Histone deacetylases 1 and 2 restrain CD4+ cytotoxic T lymphocyte differentiation. JCI Insight, 2020, 5, .	5.0	23
92	HLA class II peptide tetramersvsallergen-induced proliferation for identification of allergen-specific CD4 T cells. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 49-58.	5.7	22
93	Creation of an engineered APC system to explore and optimize the presentation of immunodominant peptides of major allergens. Scientific Reports, 2016, 6, 31580.	3.3	22
94	Glutathione-S-Transferase: A Minor Allergen in Birch Pollen due to Limited Release from Hydrated Pollen. PLoS ONE, 2014, 9, e109075.	2.5	22
95	Characterization of HLA Class II/Peptide-TCR Interactions of the Immunodominant T Cell Epitope in Art v 1, the Major Mugwort Pollen Allergen. Journal of Immunology, 2008, 181, 3636-3642.	0.8	21
96	Recombinant Mal d 1 facilitates sublingual challenge tests of birch pollenâ€allergic patients with apple allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 272-274.	5.7	21
97	The soluble isoform of human FcÉ›<scp>RI</scp> is an endogenous inhibitor of IgEâ€mediated mast cell responses. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 236-245.	5.7	21
98	Recombinant Mal d 1 is a reliable diagnostic tool for birch pollen allergenâ€“associated apple allergy. Journal of Allergy and Clinical Immunology, 2013, 132, 1008-1010.	2.9	20
99	Genetic allergen modification in the development of novel approaches to specific immunotherapy. Clinical and Experimental Allergy, 2009, 39, 1635-1642.	2.9	19
100	The T-cell response to Amb a 1 is characterized by 3 dominant epitopes and multiple MHC restriction elements. Journal of Allergy and Clinical Immunology, 2010, 126, 1068-1071.e2.	2.9	19
101	Blocking antibodies induced by allergenâ€specific immunotherapy ameliorate allergic airway disease in a human/mouse chimeric model. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 851-861.	5.7	19
102	Sublingual immunotherapy with recombinant Mal d 1 downregulates the allergenâ€specific Th2 response. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1579-1581.	5.7	19
103	Human TCR Transgenic Bet v 1-Specific Th1 Cells Suppress the Effector Function of Bet v 1-Specific Th2 Cells. Journal of Immunology, 2011, 187, 4077-4087.	0.8	18
104	Hydrocortisone enhances total IgE levels-but not the synthesis of allergen-specific IgE-in a monocyte-dependent manner. Clinical and Experimental Immunology, 2008, 101, 474-479.	2.6	17
105	Factors influencing the allergenicity and adjuvanticity of allergens. Immunotherapy, 2011, 3, 881-893.	2.0	17
106	Proteomic profiling of the weed feverfew, a neglected pollen allergen source. Scientific Reports, 2017, 7, 6049.	3.3	17
107	Birch pollen allergenâ€specific immunotherapy with glutaraldehydeâ€modified allergoid induces <scp>IL</scp>â€10 secretion and protective antibody responses. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1575-1579.	5.7	16
108	A dynamic single cell-based framework for digital twins to prioritize disease genes and drug targets. Genome Medicine, 2022, 14, 48.	8.2	16

#	Article	IF	Citations
109	Interaction of Allergens, Major Histocompatibility Complex Molecules, and T Cell Receptors: A â€˜MÃ©nage Ã Troisâ€™ That Opens New Avenues for Therapeutic Intervention in Type I Allergy. International Archives of Allergy and Immunology, 2011, 156, 27-42.	2.1	15
110	IgE and allergenâ€specific immunotherapyâ€induced IgG₄ recognize similar epitopes of Bet v 1, the major allergen of birch pollen. Clinical and Experimental Allergy, 2017, 47, 693-703.	2.9	15
111	Characterization of the T-cell response to Dau c 1, the Bet v 1-homolog in carrot. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 244-251.	5.7	15
112	4â€1BB costimulation promotes bystander activation of human CD8 TÂcells. European Journal of Immunology, 2021, 51, 721-733.	2.9	15
113	Natural Self-Assembly of Allergen-S-Layer Fusion Proteins Is No Prerequisite for Reduced Allergenicity and T Cell Stimulatory Capacity. International Archives of Allergy and Immunology, 2009, 149, 231-238.	2.1	14
114	Allergen hybrids â€“ next generation vaccines for <scp>F</scp>agales pollen immunotherapy. Clinical and Experimental Allergy, 2014, 44, 438-449.	2.9	14
115	Tâ€cellâ€derived cytokines enhance the antigenâ€presenting capacity of human neutrophils. European Journal of Immunology, 2019, 49, 1441-1443.	2.9	14
116	100 Years of Immunotherapy: The Monaco Charter. International Archives of Allergy and Immunology, 2013, 160, 346-349.	2.1	12
117	IgEâ€crossâ€blocking antibodies to Fagales following sublingual immunotherapy with recombinant Bet v 1. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2555-2564.	5.7	12
118	Tropomyosins in mosquito and house dust mite crossâ€react at the humoral and cellular level. Clinical and Experimental Allergy, 2018, 48, 1354-1363.	2.9	11
119	Alum triggers infiltration of human neutrophils ex vivo and causes lysosomal destabilization and mitochondrial membrane potentialâ€dependent NETâ€formation. FASEB Journal, 2020, 34, 14024-14041.	0.5	11
120	T Cell Epitope-Containing Domains of Ragweed Amb a 1 and Mugwort Art v 6 Modulate Immunologic Responses in Humans and Mice. PLoS ONE, 2017, 12, e0169784.	2.5	10
121	Similar Allergenicity to Different Artemisia Species Is a Consequence of Highly Cross-Reactive Art v 1-Like Molecules. Medicina (Lithuania), 2019, 55, 504.	2.0	10
122	Inflammatory immune response in recipients of transcatheter aortic valves. JTCVS Open, 2021, 6, 85-96.	0.5	10
123	Prevention of Birch Pollen-Related Food Allergy by Mucosal Treatment with Multi-Allergen-Chimers in Mice. PLoS ONE, 2012, 7, e39409.	2.5	10
124	Allergen specific responses in cord and adult blood are differentially modulated in the presence of endotoxins. Clinical and Experimental Allergy, 2008, 38, 1627-1634.	2.9	9
125	Flow cytometric analysis of cytokine expression in short-term allergen-stimulated T cells mirrors the phenotype of proliferating T cells in long-term cultures. Journal of Immunological Methods, 2011, 371, 114-121.	1.4	9
126	The diversity of Bet v 1â€“specific IgG 4 antibodies remains mostly constant during the course of birch pollen immunotherapy. Journal of Allergy and Clinical Immunology, 2015, 136, 1680-1682.e3.	2.9	9

#	Article	IF	Citations
127	T cell responses during allergen-specific immunotherapy of Type I allergy. Frontiers in Bioscience - Landmark, 2008, Volume, 6079.	3.0	9
128	Isolation of nanobodies with potential to reduce patients' IgE binding to Bet v 1. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1751-1760.	5.7	9
129	Immune mechanisms of <scp>SCIT</scp> and <scp>SLIT</scp>: facing possible differences?. Clinical and Experimental Allergy, 2014, 44, 304-306.	2.9	8
130	Alumâ€adjuvanted allergoids induce functional IgEâ€blocking antibodies. Clinical and Experimental Allergy, 2018, 48, 741-744.	2.9	8
131	The Effect of Birch Pollen Immunotherapy on Apple and rMal d 1 Challenges in Adults with Apple Allergy. Nutrients, 2020, 12, 519.	4.1	8
132	Isotype-specific binding patterns of serum antibodies to multiple conformational epitopes of Bet v 1. Journal of Allergy and Clinical Immunology, 2022, 149, 1786-1794.e12.	2.9	8
133	Two Distinct Conformations in Bet v 2 Determine Its Proteolytic Resistance to Cathepsin S. International Journal of Molecular Sciences, 2017, 18, 2156.	4.1	7
134	Endolysosomal protease susceptibility of Amb a 1 as a determinant of allergenicity. Journal of Allergy and Clinical Immunology, 2018, 141, 1488-1491.e5.	2.9	7
135	Neutrophils promote T-cellâ€“mediated inflammation in allergy. Journal of Allergy and Clinical Immunology, 2019, 143, 1923-1925.e3.	2.9	7
136	Adjuvants and Vaccines Used in Allergen-Specific Immunotherapy Induce Neutrophil Extracellular Traps. Vaccines, 2021, 9, 321.	4.4	7
137	Neutrophils-typical atypical antigen presenting cells?. Immunology Letters, 2022, 247, 52-58.	2.5	7
138	The secretome of irradiated peripheral blood mononuclear cells attenuates activation of mast cells and basophils. EBioMedicine, 2022, 81, 104093.	6.1	7
139	4th European Congress of Immunology â€“ ECI 2015. European Journal of Immunology, 2015, 45, 1888-1891.	2.9	5
140	How Do Pollen Allergens Sensitize?. Frontiers in Molecular Biosciences, 0, 9, .	3.5	5
141	TGF-beta1 impairs homocysteine metabolism in human renal cells: possible implications for transplantation. Transplant International, 2003, 16, 843-848.	1.6	4
142	Dramatically decreased T cell responses but persistent IgE upon reduced pollen exposure. Immunobiology, 2019, 224, 645-648.	1.9	4
143	NSG mice humanized with allergenâ€specific Tâ€cell lines as in vivo model of respiratory allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2081-2084.	5.7	4
144	Proteomic profiling of commercial dust mite skin prick test solutions and allergy vaccines from India. World Allergy Organization Journal, 2021, 14, 100516.	3.5	3

#	Article	IF	Citations
145	Treatment Approaches to Food Allergy. Handbook of Experimental Pharmacology, 2021, 268, 173-193.	1.8	3
146	Tropomyosin is no accurate marker allergen for diagnosis of shrimp allergy in Central Europe. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1921-1923.	5.7	3
147	6th International Symposium on Molecular Allergology (ISMA). Clinical and Translational Allergy, 2016, 6, .	3.2	2
148	Initiating yellow jacket venom immunotherapy with a 100-Î¼g dose: A challenge?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1332-1334.e4.	3.8	2
149	Birch Pollen-Related Food Allergy: An Excellent Disease Model to Understand the Relevance of Immunological Cross-Reactivity for Allergy. , 0, , .		2
150	Harmonization of the Genetic Code Effectively Enhances the Recombinant Production of the Major Birch Pollen Allergen Bet v 1. International Archives of Allergy and Immunology, 2018, 177, 116-122.	2.1	1
151	Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-Î³ production in cells from allergic individuals and inhibit IgE synthesis in vitro. , 0, .		1
152	126â€ƒCreation of a Humanized Model for Respiratory Allergy Using a Human Mugwort-specificT-Cell Receptor and HLA-DR1. World Allergy Organization Journal, 2012, 5, S42.	3.5	0
153	Immunoglobulin E and G4 epitopes of the major allergen of birch pollen Bet v 1 share residues critical for antibody binding. Clinical and Translational Allergy, 2013, 3, O15.	3.2	0
154	Editor-in-Chief Barbara Bohle. International Archives of Allergy and Immunology, 2013, 162, 274-274.	2.1	0
155	Who Is Who in the Journal?. International Archives of Allergy and Immunology, 2013, 162, 1-1.	2.1	0
156	Glutathione-s-transferase is a minor allergen in birch pollen because of restricted release from hydrated pollen grains. Clinical and Translational Allergy, 2014, 4, .	3.2	0
157	Bet v 1 and homologous food allergens are similarly processed by antigen-presenting cells but differ in T cell reactivity. Clinical and Translational Allergy, 2014, 4, .	3.2	0
158	Immunological mechanisms in sublingual immunotherapy. Drugs of Today, 2008, 44 Suppl B, 95-6.	1.1	0